|
KMID : 0941820210310030188
|
|
Korean Journal of Clinical Pharmacy
2021 Volume.31 No. 3 p.188 ~ p.197
|
|
|
Usage Patterns and Incidence of Thyroid-related Adverse Events in Patients Treated with PD-1 Inhibitors
|
|
Hwang Seo-Young
Kim Heui-Jae
Chung Seon-Young
Min Myung-Sook
Suh Dong-Churl
|
|
|
Abstract
|
|
|
Objective: PD-1 inhibitors have demonstrated improved health outcomes in cancer patients. PD-1 inhibitors are well-tolerated andassociated with immune-related adverse events. The objectives of this study are to analyze use patterns of PD-1 inhibitors in patientswith cancer and to investigate the incidence of thyroid-related adverse reactions in patients treated with PD-1 inhibitors.
Methods:The study included patients who had been administered PD-1 inhibitors (either nivolumab or pembrolizumab) at the SamsungMedical Center between October 1, 2016 and June 30, 2017. Data was collected from electronic medical records and tested usingMann-Whitney tests and Chi-Square tests for statistical significance. Associations between PD-1 inhibitors and incidence of adverseevents were tested using Cox regression for age, gender, BMI, ECOG PS and medication.
Results: Two hundred fifteen patientswere identified as eligible for analyses. Thyroid-related adverse events occurred in 20% of patients (n=43). Thyroid function tests(TFTs) was performed in 109 patients (50.7%). Positive results of PD-L1 testing were found in 53.2% of the 94 patients who had thetest. Approved doses of nivolumab (3 m/kg) and pembrolizumab (200 mg) were administered in 70.4% and 53% of patients,respectively. The analysis of risk factor of thyroid-related adverse reaction did not show statistically significant differences (Coxregression).
Conclusion: Thyroid-related adverse events are common in patients treated with PD-1 inhibitors and hypothyroidism isthe most frequent adverse reaction. Routine TFTs monitoring is strongly recommended to evaluate thyroid function in real-worldclinical practice.
|
|
|
KEYWORD
|
|
|
PD-1 inhibitors, nivolumab, pembrolizumab, thyroid, adverse events
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|